Showing 15 posts of 29 posts found.


Court sides with Amgen in Sandoz’ challenge over patent on Enbrel

August 12, 2019
Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …


Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada

May 17, 2019
Medical Communications Gilead, HIV, PrEP, Truvada, patent, pharma

On 16 May, Gilead CEO Daniel O’Day was grilled over the $1,780 price tag on PrEP drug Truvada in a …


Jury upholds Amgen’s patent validity for Repatha, deflecting challenge from Sanofi and Regeneron

February 26, 2019
Manufacturing and Production, Sales and Marketing Amgen, Regeneron, Repatha, Sanofi, patent, pharma

Amgen is celebrating after a Delaware jury backed the validity of two of its patents against challenges from Regeneron and …


Counterfeit drugs – countering the lies

February 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Counterfeit drugs, IP, counterfeit medicines, falsified medicines, intellectual property, law, legal, patent

As the Falsified Medicines Directive comes into effect in February 2019, Louis Goss fact checks ‘common sense’ claims on counterfeit …

Novartis buys eczema drug in €95m deal

July 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent

Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …

Allergan’s patent gamble fails

February 27, 2018
Manufacturing and Production, Medical Communications Allergan, Mylan, biotech, drugs, patent, pharma, pharmaceutical

Allergan’s patent deal with the Saint Regis Mohawk Tribe, in an attempt to protect itself from an inter partes review …


US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …


Indivior reaches settlement with Mylan over patent dispute

September 25, 2017
Sales and Marketing Mylan, indivior, patent, pharma, pharmaceutical, suboxone

Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by …


A patent analytics study of the Australian pharmaceutical industry

March 24, 2017
Medical Communications Australia, patent, pharmaceutical

This report provides an analysis of the Australian pharmaceutical and biopharmaceutical industry through the lens of patents. By using the …


Lilly three strikes in three years not out in Teva patent challenge

January 13, 2017
Medical Communications, Sales and Marketing Eli Lilly, Teva, generics, lilly, patent

Eli Lilly has successfully won a major patent case against Teva Pharmaceuticals, with the case being decided at the US …


Amgen’s patent win upheld against Sanofi-Regeneron

January 4, 2017
Medical Communications, Research and Development Amgen, Regeneron, Sanofi, patent

In March 2016, Amgen won two major patent cases against Sanofi and Regeneron over their drug, Praleunt, after it was …


J&J loses Remicade patent fight, pledges to continue fight against biosimilars

August 18, 2016
Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent

Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …


US court rules in favour of UCB in patent dispute, shares jump

August 16, 2016
Manufacturing and Production, Research and Development, Sales and Marketing UCB, lacosamide, patent, vimpat

UCB has received a major boost after a Delaware district court confirmed the validity of the company’s patents on one …


AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor

July 11, 2016
Sales and Marketing AstraZeneca, Crestor, US FDA, patent, regulation

Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from …


Judge reverses verdict in MSD/Gilead hepatitis C dispute

June 7, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead, MSD, Merck, dispute, patent, reversal, sovaldi

A US district judge has reversed a previous court decision which favoured MSD, called Merck in the US, over Gilead …

Latest content